A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

Not Applicable

Completed

• Conditions: HIV Infections; Leukoencephalopathy, Progressive Multifocal

• Registration Number: NCT00002274
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Status Verified: 2007-10
• Last Update Submitted: 2007-10-01
• Last Update Posted: 2007-10-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Bristol - Myers Squibb Co; 🇺🇸 Princeton, New Jersey, United States